Lonza has introduced an integrated drug development model that reduces timelines for certain bispecific antibodies from 22–24 months to just 13 months. The approach applies parallel processing, ...

Funding Fundamentals is part of BDCC’s broader commitment to supporting entrepreneurs and small businesses across Southern Vermont by providing accessible education, technical assistance, and ...

Completed enrollment in first cohort of Phase 1b challenge study evaluating CDI-988 as a preventive and as a treatment for ...

Iopofosine I-131 achieved an overall response rate of 83.6% and a major response rate of 61.8% in patients with relapsed or ...

Record Q1 gross margin of 35%, highest Q1 in the Company's historyRevenue of $5.6M, reflecting typical seasonal patterns and ...

In May 2026, the U.S. defense landscape is undergoing a critical shift: the F-35 Lightning II, once the cornerstone of American air superiority, is grappling with severe Block 4 upgrade delays that ...

Bank of America Global Healthcare Conference 2026 May 12, 2026 11:40 AM EDTCompany ParticipantsMatthew Klein - CEO ...

Operator: Greetings, and welcome to the PDS Biotech First Quarter 2026 Earnings Conference Call. [Operator Instructions] It ...

Carl Zeiss Meditec AG ( CZMWY) Q2 2026 Earnings Call May 12, 2026 3:30 AM EDT ...

Papzimias: A first-in-class FDA-approved gene therapy indicated for adult patients with recurrent respiratory papillomatosis (RRP), based on a proprietary adenovector technology platform. AdenoVerse ...

Honorable Michael J. Borders, assistant secretary of the Air Force for energy, installations and environment, visited Space Launch Delta 45 ...

Thank you for joining us in our third quarter earnings release this morning we not only reiterated our expectation of a near term resurgence of growth, but we also increased our outlook. I'm going to ...